Steminent Biotherapeutics (ROCO:7729) Stock Based Compensation: NT$11.79 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:7729 Steminent Biotherapeutics Inc ROCO:7729
9 GF Score
Price NT$76.60
! 4 Warning Signs
View Full Analysis

What is Steminent Biotherapeutics Stock Based Compensation?

Steminent Biotherapeutics ROCO:7729 +2.54% 9 Stock Based Compensation is NT$11.79 Mil as of Dec. 2025. GuruFocus rates ROCO:7729 with a GF Score™ of 9/100. The stock has 4 warning signs investors should review.

Steminent Biotherapeutics's Stock Based Compensation for the six months ended in Dec. 2025 was NT$7.04 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 was NT$11.79 Mil.

Steminent Biotherapeutics Stock Based Compensation Related Terms

Steminent Biotherapeutics Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Steminent Biotherapeutics's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Steminent Biotherapeutics Stock Based Compensation Chart

Steminent Biotherapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial 0.63 2.72 8.58 15.88 11.79

Steminent Biotherapeutics Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.51 11.98 3.91 4.75 7.04
ROCO:7729
9GF Score
Steminent Biotherapeutics Inc ROCO:7729
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Steminent Biotherapeutics Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$11.79 Mil.

What does a Stock Based Compensation of NT$11.79 Mil mean?
Steminent Biotherapeutics (ROCO:7729) has a Stock Based Compensation of NT$11.79 Mil as of Dec. 2025. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Steminent Biotherapeutics and its competitors.
Is Steminent Biotherapeutics' Stock Based Compensation too high?
Steminent Biotherapeutics' current Stock Based Compensation is NT$11.79 Mil. Overall, Steminent Biotherapeutics has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Steminent Biotherapeutics' Stock Based Compensation compare to VRTX and REGN?
Steminent Biotherapeutics' Stock Based Compensation of NT$11.79 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Steminent Biotherapeutics and its competitors. Steminent Biotherapeutics's current Stock Based Compensation is NT$11.79 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Steminent Biotherapeutics stock overvalued right now?
Steminent Biotherapeutics (ROCO:7729) has a current Stock Based Compensation of NT$11.79 Mil. The current Stock Based Compensation is NT$11.79 Mil. Steminent Biotherapeutics' overall GF Score™ is 9/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Steminent Biotherapeutics (ROCO:7729), the current Stock Based Compensation is NT$11.79 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Steminent Biotherapeutics Business Description

Address No.16,Wenhu Street, Neihu District, Taipei, TWN, 11445
Steminent Biotherapeutics Inc is a international stem cell biopharmaceutical company which has stable and efficient stem cell platform technology, aiming to develop live cell drugs to treat degenerative diseases as well as acute and life-threatening diseases. With its Stemchymal which is proprietary technology platform generating the standardized, clinical grade, allogeneic stem cells isolated from human adipose tissue. It is operated in strict compliance to regulations of Taiwan, the US, and Japan.
9GF Score

Get the complete analysis for ROCO:7729

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$76.60
Price